Home-based Growth Charts in Indonesia

July 31, 2023 updated by: Boston University

Impact of Home-based Growth Charts on Child Linear Growth in Indonesia

The investigators developed a home-based growth chart that offers a simple and inexpensive way for caregivers to have access to simple health and nutrition information guided by behavioural economics analysis as well as to track their child's linear growth, empowering them to act to improve their child's nutrition. Results from a pilot study conducted in rural Zambia suggest that growth charts installed in homes can increase awareness and reduce early-life growth deficits, particularly among children experiencing growth faltering. The main objective of this study is to assess the impact and cost-effectiveness of growth charts through a cluster-randomized trial in Indonesia. The primary outcome is child height-for-age z-score.

Study Overview

Detailed Description

The study is divided into two phases. In the first phase, growth chart development activities will be conducted in two villages in each of Manggarai Timur and Trenggalek districts to ensure the chart design is compatible with the local context and chart information is understandable to caregivers. Focus group discussions (FGDs), key informant interviews (KIIs), and door-to-door user testing will be conducted in each village. Results from the FGDs and KIIs will inform a draft growth chart design that will then be user tested in 10 households in each village. Qualitative interviews will be conducted with each household approximately two weeks after chart installation to gather insights on the usability of the growth chart. The chart design will then be finalized for use in the second phase of the study.

In the second phase, 1,480 caregiver-child dyads will be recruited and enrolled in the study as part of a baseline survey. Dyads will be sampled using a two-stage procedure. 110 villages will be selected proportionate to national census population size. All sub-villages ("dusun") within selected villages will be randomly assigned into two groups: 1) Growth chart; and 2) Control. Eligible caregiver-child dyads with children between 9 and 14 months will be selected from each sub-village.

Study Type

Interventional

Enrollment (Actual)

1487

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Jakarta, Indonesia
        • The Abdul Latif Jameel Poverty Action Lab Southeast Asia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

9 months to 1 year (Child)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Caregivers must be 19 - 55 years old
  • One child of either gender, 9-14 months old
  • Caregiver can have other children
  • Caregiver of any occupation and income level
  • Live in Manggarai Timur and Trenggalek during inception

Exclusion Criteria:

-Caregivers with a cognitive disability

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention group
Household receives the home-based growth chart
The growth chart contains simple information of nutritious food, health, and sanitation information at the top and height chart is located at the bottom where caregivers can measure their child's linear growth. Growth charts will be installed in intervention group homes just after the baseline survey.
Households will be visited for baseline surveys.
Households will be revisited after 1 year of grace-period for baseline end line surveys.
The child's height-for-age and weight-for-age will be measured for participating dyads at the time of the baseline and end line surveys.
Active Comparator: Control group
Household does not receive the home-based growth chart
Households will be visited for baseline surveys.
Households will be revisited after 1 year of grace-period for baseline end line surveys.
The child's height-for-age and weight-for-age will be measured for participating dyads at the time of the baseline and end line surveys.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Child height for age z-score (HAZ)
Time Frame: 12 months
Height/length data will be converted to height for age z-score (HAZ) using WHO (World Health Organization) growth standards.
12 months
Child stunting
Time Frame: 12 months
Child stunting is defined as height for age z-score (HAZ) < -2
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Child weight for age z-score (WAZ)
Time Frame: 12 months
Weight data will be converted to weight for age z-score (WAZ) using WHO growth standards.
12 months
Early child development (ECD)
Time Frame: 12 months
ECD will be evaluated with the Caregiver Reported Early Childhood Development Instruments (CREDI) Long Form which assesses child cognitive, motor, language, and social-emotional development. It provides a global, population-level measure of ECD for children in the 0-3 age range. The long form has about 60 items coded as Yes=1, No=0 and Don't know=8. The CREDI Long Form creates domain-specific developmental scores.
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Peter C Rockers, ScD, MPH, BU School of Public Health

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 14, 2022

Primary Completion (Estimated)

July 1, 2024

Study Completion (Estimated)

July 1, 2024

Study Registration Dates

First Submitted

January 7, 2020

First Submitted That Met QC Criteria

January 7, 2020

First Posted (Actual)

January 10, 2020

Study Record Updates

Last Update Posted (Actual)

August 2, 2023

Last Update Submitted That Met QC Criteria

July 31, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • H-39613
  • 73494 (Other Grant/Funding Number: Department of Foreign Affairs and Trade, Australia)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Child Growth

Clinical Trials on Home-based growth charts

3
Subscribe